Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Nov;75(11):1553–1557. doi: 10.1136/jnnp.2003.014282

Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin

A Zahavi 1, J Geertzen 1, B Middel 1, M Staal 1, J Rietman 1
PMCID: PMC1738793  PMID: 15489386

Abstract

Objectives: To evaluate long term change in impairment, disability, and health related functional status in patients with severe spasticity who received intrathecal baclofen.

Methods: A long term (more than five years) observational longitudinal follow up study assessing 21 patients who received intrathecal baclofen given by programmable pump. Patients had chronic disabling spasticity which did not respond to oral antispasmolytic agents. Clinical efficacy was assessed by the Ashworth scale and spasm score; disability by the expanded disability status scale (EDSS), ambulation index (AI), and incapacity status scale (ISS); and health related quality of life by the sickness impact profile (SIP) and the Hopkins symptom checklist (HSCL).

Results: Compared with pretreatment values, there was a significant improvement in clinical efficacy (Ashworth scale and spasm score, p<0.05) but a small but significant worsening of disability (EDSS, AI, and ISS, p<0.05). Comparing pretreatment with 26 weeks after pump implantation, a worsening was observed in disability (EDSS and ISS, p<0.05) and perceived health status (SIP, psychosocial dimension, p<0.05).

Conclusions: Long term administration of intrathecal baclofen delivered by an implanted programmable pump resulted in improved clinical efficacy but not in improvement in disability or perceived health status.

Full Text

The Full Text of this article is available as a PDF (72.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASHWORTH B. PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. Practitioner. 1964 Apr;192:540–542. [PubMed] [Google Scholar]
  2. Abel N. A., Smith R. A. Intrathecal baclofen for treatment of intractable spinal spasticity. Arch Phys Med Rehabil. 1994 Jan;75(1):54–58. [PubMed] [Google Scholar]
  3. Aisen M. L., Dietz M. A., Rossi P., Cedarbaum J. M., Kutt H. Clinical and pharmacokinetic aspects of high dose oral baclofen therapy. J Am Paraplegia Soc. 1992 Oct;15(4):211–216. doi: 10.1080/01952307.1992.11761520. [DOI] [PubMed] [Google Scholar]
  4. Albright A. Leland, Gilmartin Richard, Swift Dale, Krach Linda E., Ivanhoe Cindy B., McLaughlin John F. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg. 2003 Feb;98(2):291–295. doi: 10.3171/jns.2003.98.2.0291. [DOI] [PubMed] [Google Scholar]
  5. Azouvi P., Mane M., Thiebaut J. B., Denys P., Remy-Neris O., Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil. 1996 Jan;77(1):35–39. doi: 10.1016/s0003-9993(96)90217-8. [DOI] [PubMed] [Google Scholar]
  6. Bergner M., Bobbitt R. A., Carter W. B., Gilson B. S. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981 Aug;19(8):787–805. doi: 10.1097/00005650-198108000-00001. [DOI] [PubMed] [Google Scholar]
  7. Coffey J. R., Cahill D., Steers W., Park T. S., Ordia J., Meythaler J., Herman R., Shetter A. G., Levy R., Gill B. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993 Feb;78(2):226–232. doi: 10.3171/jns.1993.78.2.0226. [DOI] [PubMed] [Google Scholar]
  8. Gardner B., Jamous A., Teddy P., Bergstrom E., Wang D., Ravichandran G., Sutton R., Urquart S. Intrathecal baclofen--a multicentre clinical comparison of the Medtronics Programmable, Cordis Secor and Constant Infusion Infusaid drug delivery systems. Paraplegia. 1995 Oct;33(10):551–554. doi: 10.1038/sc.1995.119. [DOI] [PubMed] [Google Scholar]
  9. Gianino J. M., York M. M., Paice J. A., Shott S. Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs. 1998 Feb;30(1):47–54. doi: 10.1097/01376517-199802000-00006. [DOI] [PubMed] [Google Scholar]
  10. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  11. Mertens P., Parise M., Garcia-Larrea L., Benneton C., Millet M. F., Sindou M. Long-term clinical, electrophysiological and urodynamic effects of chronic intrathecal baclofen infusion for treatment of spinal spasticity. Acta Neurochir Suppl. 1995;64:17–25. doi: 10.1007/978-3-7091-9419-5_5. [DOI] [PubMed] [Google Scholar]
  12. Meythaler J. M., Steers W. D., Tuel S. M., Cross L. L., Haworth C. S. Continuous intrathecal baclofen in spinal cord spasticity. A prospective study. Am J Phys Med Rehabil. 1992 Dec;71(6):321–327. doi: 10.1097/00002060-199212000-00003. [DOI] [PubMed] [Google Scholar]
  13. Middel B., Kuipers-Upmeijer H., Bouma J., Staal M., Oenema D., Postma T., Terpstra S., Stewart R. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):204–209. doi: 10.1136/jnnp.63.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nance P., Schryvers O., Schmidt B., Dubo H., Loveridge B., Fewer D. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci. 1995 Feb;22(1):22–29. doi: 10.1017/s0317167100040452. [DOI] [PubMed] [Google Scholar]
  15. Ordia J. I., Fischer E., Adamski E., Spatz E. L. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg. 1996 Sep;85(3):452–457. doi: 10.3171/jns.1996.85.3.0452. [DOI] [PubMed] [Google Scholar]
  16. Parke B., Penn R. D., Savoy S. M., Corcos D. Functional outcome after delivery of intrathecal baclofen. Arch Phys Med Rehabil. 1989 Jan;70(1):30–32. [PubMed] [Google Scholar]
  17. Patterson V., Watt M., Byrnes D., Crowe D., Lee A. Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. J Neurol Neurosurg Psychiatry. 1994 May;57(5):582–585. doi: 10.1136/jnnp.57.5.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Penn R. D. Intrathecal baclofen for severe spasticity. Ann N Y Acad Sci. 1988;531:157–166. doi: 10.1111/j.1749-6632.1988.tb31822.x. [DOI] [PubMed] [Google Scholar]
  19. Penn R. D. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg. 1992 Aug;77(2):236–240. doi: 10.3171/jns.1992.77.2.0236. [DOI] [PubMed] [Google Scholar]
  20. Penn R. D., Kroin J. S. Continuous intrathecal baclofen for severe spasticity. Lancet. 1985 Jul 20;2(8447):125–127. doi: 10.1016/s0140-6736(85)90228-4. [DOI] [PubMed] [Google Scholar]
  21. Penn R. D., Kroin J. S. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg. 1987 Feb;66(2):181–185. doi: 10.3171/jns.1987.66.2.0181. [DOI] [PubMed] [Google Scholar]
  22. Penn R. D., Savoy S. M., Corcos D., Latash M., Gottlieb G., Parke B., Kroin J. S. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989 Jun 8;320(23):1517–1521. doi: 10.1056/NEJM198906083202303. [DOI] [PubMed] [Google Scholar]
  23. Saltuari L., Kronenberg M., Marosi M. J., Kofler M., Russegger L., Rifici C., Bramanti P., Gerstenbrand F. Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity. Acta Neurol (Napoli) 1992 Jun;14(3):187–194. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES